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Abstract
Background: Adverse events in health care entail substantial burdens to health care systems, institutions, and patients.
Retrospective trigger tools are often manually applied to detect AEs, although automated approaches using electronic health
records may offer real-time adverse event detection, allowing timely corrective interventions.
Objective: The aim of this systematic review was to describe current study methods and challenges regarding the use of automatic
trigger tool-based adverse event detection methods in electronic health records. In addition, we aimed to appraise the applied
studies’ designs and to synthesize estimates of adverse event prevalence and diagnostic test accuracy of automatic detection
methods using manual trigger tool as a reference standard.
Methods: PubMed, EMBASE, CINAHL, and the Cochrane Library were queried. We included observational studies, applying
trigger tools in acute care settings, and excluded studies using nonhospital and outpatient settings. Eligible articles were divided
into diagnostic test accuracy studies and prevalence studies. We derived the study prevalence and estimates for the positive
predictive value. We assessed bias risks and applicability concerns using Quality Assessment tool for Diagnostic Accuracy
Studies-2 (QUADAS-2) for diagnostic test accuracy studies and an in-house developed tool for prevalence studies.
Results: A total of 11 studies met all criteria: 2 concerned diagnostic test accuracy and 9 prevalence. We judged several studies
to be at high bias risks for their automated detection method, definition of outcomes, and type of statistical analyses. Across all
the 11 studies, adverse event prevalence ranged from 0% to 17.9%, with a median of 0.8%. The positive predictive value of all
triggers to detect adverse events ranged from 0% to 100% across studies, with a median of 40%. Some triggers had wide ranging
positive predictive value values: (1) in 6 studies, hypoglycemia had a positive predictive value ranging from 15.8% to 60%; (2)
in 5 studies, naloxone had a positive predictive value ranging from 20% to 91%; (3) in 4 studies, flumazenil had a positive
predictive value ranging from 38.9% to 83.3%; and (4) in 4 studies, protamine had a positive predictive value ranging from 0%
to 60%. We were unable to determine the adverse event prevalence, positive predictive value, preventability, and severity in
40.4%, 10.5%, 71.1%, and 68.4% of the studies, respectively. These studies did not report the overall number of records analyzed,
triggers, or adverse events; or the studies did not conduct the analysis.
Conclusions: We observed broad interstudy variation in reported adverse event prevalence and positive predictive value. The
lack of sufficiently described methods led to difficulties regarding interpretation. To improve quality, we see the need for a set
of recommendations to endorse optimal use of research designs and adequate reporting of future adverse event detection studies.
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Introduction
In recent decades, patient safety and quality of care have become
a top priority in health care [1-3]. This has led to significant
progress, especially regarding innovative use of electronic health
records (EHRs). Adverse events (AEs), injuries attributed to
medical care that are independent of the patient’s underlying
condition, nevertheless remain a persistent problem. Apart from
the impact on patients, they entail large human and financial
burdens at every health care system level [4]. Regarding patient
health, AEs’ negative consequences include extended hospital
stays, higher readmission rates, and higher mortality [5].
Furthermore, AEs may lead to the patients’ and their families’
loss of trust in their health care professionals (HCPs), their
health care system, or both [3]. The estimated prevalence of
AEs in hospital inpatients ranges from 3% to 40% in acute care
settings [2,6-10]. The wide range reflects the challenges involved
in detecting and tracking AEs accurately [11].
To improve patient safety, health care organizations need valid
and reliable tools to detect and assess AEs [12]. Several tools
exist, but their ability to identify AEs is limited, and none of
them are broadly accepted [13-15]. Currently, enumerating
specific events that endanger patients depends mainly on
voluntarily reporting by health care staff [16,17]. Systematic
evaluations of this approach showed endemic underreporting,
with only 2% to 8% of all harmful events being identified
[18-20]. To depict the situation more robustly, the US Agency
for Healthcare Research and Quality (AHRQ) published a set
of Patient Safety Indicators (PSIs). Using administrative
datasets, PSIs identify potential AEs, but are highly susceptible
to variations in coding practice and are limited by many
outcomes being easily concealed in the medical record [14].
Therefore, they miss a substantial fraction of AEs (low
sensitivity), while producing a substantial fraction of false
positive results (low specificity) [13,21].
One promising method is the Global Trigger Tool (GTT),
developed by the Institute for Healthcare Improvement (IHI)
[22]. Providing a structured method for identifying AEs from
patient records [23,24], the GTT is a retrospective record review
instrument that uses a list of triggers (or clues), ie, data elements
within the health record, to alert reviewers to the potential
presence of AEs [22,25]. By focusing on triggers within patient
records, the GTT has demonstrated to identify up to ten times
as many AEs as other detection methods [13]. Various studies
have used the GTT, where some modified the methods, eg, by
modifying the set of triggers, or by modifying the review process
(eg, one reviewer instead of two for trigger identification). We
refer to these modified versions as trigger tool methodology,
reserving the term GTT methodology for the IHI’s original
procedures [24].
The trigger tool was developed as a manual approach, ie, for
application by HCPs reviewing patient records. Recently, an
increasing interest developed for semi or fully automated AE
detection methods using EHRs where lesser time and personnel
resources are required for the AE identification [25-28].
Prospective AE detection would supply real-time feedback to
HCPs, allowing timely interventions. The development of
automated surveillance systems using EHR data has greatly
facilitated AEs’ identification [28].
Semi or fully automated AEs detection methods show promise
to efficiently measure AEs. Nevertheless, evidence need to be
summarized based on the current literature to gather information
for future development and implementation in a health care
organization. As a variety of AEs’ detection methods exist, we
decided to focus on trigger tool–based AEs detection methods
only, allowing comparisons between studies as suggested in a
previous systematic review on automated detection of patient
harm [29]. As trigger tool methodology has shown higher
sensitivity compared with other detection methods, we
considered the manual trigger tool as the gold standard. This
systematic review aimed to describe current study methods and
challenges regarding the use of automatic trigger tool–based
AE detection methods in EHRs in acute care settings. In
addition, we aimed to appraise the applied studies’ designs and
to synthesize estimates of AE prevalence and diagnostic test
accuracy (DTA) of automatic detection methods using manual
trigger tool as a reference standard.
Methods
Search Strategy and Study Selection
This systematic review followed the recommendations of the
Cochrane Handbook for Systematic Reviews of Diagnostic Test
Accuracy [30], the Cochrane Handbook for Systematic Reviews
of Interventions [31], and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines for the
reporting of systematic reviews [32].
Hausner et al’s approach was applied to develop a robust search
strategy (Multimedia Appendix 1) [33,34]. In PubMed’s basic
search mode, we entered the following medical subject headings
(MeSH) and free-text terms for title and abstract fields: (trigger
OR triggers) AND (chart OR charts OR identif* OR record OR
records) AND (adverse OR medical errors). The focus of the
search was on “trigger” and not on GTT, as we aimed to include
studies using variations of the original GTT. The search strategy
was transposed to EMBASE, CINAHL, and the Cochrane
Library, and terms were mapped to the appropriate keywords
(eg, from MeSH to Emtree). Studies published in English,
French, German, Italian, or Spanish were considered without
restrictions concerning the years of the publication. In addition
to searching the bibliographic databases, the team identified
additional relevant literature from most common journals
publishing in the field of trigger tool: BMJ Quality & Safety,
Journal of Patient Safety, and International Journal for Quality
in Health. For pragmatic reasons, the research team decided to
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limit the hand search of the most common journals to the years
2014 to 2017. The search was conducted in November 2015
with updates in April 2016 and July 2017.
We included observational studies that applied a trigger-based
tool to detect AEs in EHRs in any acute care setting. We defined
the target population of interest as patients hospitalized for at
least 48 hours for any reason. The evaluated trigger tool
approach (index test) had to involve either semi (ie, one part of
the process still manual) or fully automatic identification of AEs
[29]. Regarding DTA studies, we opted for a reference standard
that produced a relatively low rate of missed AEs alongside an
acceptable rate of false positive test results (events flagged as
AEs that, upon examination, did not qualify as AEs). As shown
by Classen et al (2011), manual trigger-based tools met our
target criteria [13]. We excluded studies from nonhospital
settings (eg, long-term care), outpatient clinics, or that concerned
with nonprimary research (eg, systematic reviews or editorials).
The eligible articles were divided into two sets: (1) an automated
trigger tool in comparison with a manual trigger tool method
for AE detection, potentially enabling the evaluation of the
trigger tool’s DTA (diagnostic test accuracy studies) and (2)
application of an automated trigger tool without
cross-verification with a manual trigger tool method, enabling
us to synthesize the prevalence of AEs and the applied methods.
We refer to the latter group as “prevalence studies ” throughout
this paper.
Data Extraction
Two main reviewers (SNM and MS) each screened half of the
retrieved titles and abstracts for relevance according to the
criteria outlined above. The other members of the research team
each screened a quarter of the retrieved titles and abstracts,
allowing double screening for all citations. Full-text screening
was independently assessed by the main two reviewers, where
disagreements were resolved by discussion, or by consulting
the entire research team, if necessary.
Detailed study information was extracted into tables by SNM
and a master student as part of her training. We used
standardized piloted extraction sheets to tabulate variables
related to design, sample population characteristics, applied
trigger tool methodology, type and number of reviewers and
triggers, and outcome data expressed as AE prevalence (overall
and by AE type). To estimate DTA, we used 2x2 tables.
Whenever possible, we derived the positive predictive value
(PPV) of the triggers used. PPV is calculated by dividing the
number of true positive triggers related to confirm AEs by the
total number of positive triggers.
Unresolved disagreements or uncertainties between SNM and
the master student were discussed and resolved in the research
team, which included experienced systematic review and GTT
methodologists, clinicians, and nurses, each with more than 10
years of experience in their specialty.
Quality Assessment
We assessed the risk of bias and the concerns regarding
applicability of all included studies. With respect to DTA, we
assessed the quality of the included studies with the QUADAS-2
instrument, which we adapted for use as recommended by its
authors [35]. The tool consists of four domains: (1) patient
selection, (2) index test, (3) reference standard, and (4) flow
and timing. Each domain contains signaling questions for risk
of bias and concerns regarding applicability except the domain
flow and timing. Each signaling question has three answer
options: yes, no, and unclear. On the basis of the overall rating
of the reviewers, an assessment can be made in each domain
concerning bias and applicability. For example, one signaling
question in the domain patient selection is, “Was a consecutive
or random sample of patients enrolled?” All adaptations of the
instrument are explained in Multimedia Appendix 2.
For prevalence studies, the research team generated a new tool
based on the structure of the QUADAS-2 instrument to assess
the risk of bias and concerns regarding applicability. The new
tool consisted of six domains: patient selection, reviewer and
algorithm selection, automatic detection method, outcomes, and
flow and timing. All but outcomes and flow and timing included
a section on risk of bias and concern regarding applicability,
including signaling questions (Multimedia Appendix 3). The
goal of this quality assessment was to verify the quality of the
semi or fully automated trigger tool studies by focusing
specifically on algorithm development and the basis for choosing
each trigger.
Quality assessment process was conducted by one reviewer
(SNM), and each research team member received at least one
study to compare the results with SNM. Members did each task
individually; then all results were discussed jointly by the
multidisciplinary research team.
Statistical Analyses
As we anticipated a paucity of evidence on DTA data, we
deemed formal meta-analyses not feasible. For the total number
of AEs and each type of AE, we present percentages with 95%
CIs for prevalence, PPV, and rate of false negative test results.
For the prevalence studies, we provided percentages for
prevalence and PPV with 95% CIs, for AE overall and per type
of trigger.
Results
Search Strategy and Study Selection
After removing duplicates, 2658 citations were identified via
our search strategy, the core journals, and our personal library.
Of these, 11 met all selection criteria: 2 concerned diagnostic
test accuracy studies and and 9 prevalence studies. A detailed
view of the included studies is provided with a flow diagram in
Figure 1.
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Figure 1. Flow diagram of the number of studies found with the search strategy, studies screened, and reasons for exclusions. Eleven studies fulfilled
all inclusion and exclusion criteria.
Description of Included Studies
The studies were published from 2005 to 2016. Of these, 9 were
conducted in the United States [25,36-43], 1 in Denmark [44],
and 1 in the United Kingdom [45]. Concerning the study
populations, 7 were conducted among pediatric or neonatal
patients [25,36,37,39,40,43,45], 3 among adults [38,41,42], and
1, published in abstract form only, provided no population
information [44]. Two studies conducted multisite trigger tool
research [25,42]. The bed capacity of the hospitals involved
ranged from 26 to 1000 beds, with a median of 306. One study
provided no information on bed capacity [36]. Further details
concerning the design and the characteristics are summarized
in Table 1.
One study explicitly followed the IHI guidelines for GTT [42],
whereas the other studies used different trigger tool approaches
or did not specify whether they followed the IHI guidelines.
Concerning methodology, 6 studies addressed only adverse drug
events (ADEs) [36,38,39,42,43,45], and only 1 used a fully
automatic AE detection approach [44]. Definitions used to define
and reference AEs varied [36-38,40-43,45] or were absent
[25,39,44]. Seven studies used decision or agreement of the
reviewer(s) to confirm an AE, without reference to the indexing
method used [25,36-40,43]; and 2 studies omitted any
explanation of the process [44,45]. Five studies did not consider
preventability [38,39,42,44,45]; in the remainder, definitions
varied. Three studies used the definition of a preventable AE
as an “event leading to action deviating from the local standard
of care” [37,40,43]; one study used a scale from “1—virtually
no evidence for management causation” to “6—virtually certain
evidence for management causation,” but without describing
the applied cutoff [36]. One study used a 6-point confidence
scale from “1—virtually no evidence of preventability” to
“6—virtually certain evidence of preventability,” with a score
≥4 denoting preventability [41]; and one study merely described
that preventability was determined by the reviewers’ decision
[25]. Five studies assessed AEs’ severity using the National
Coordinating Council for Medication Error Reporting and
Prevention (NCC MERP) categories [25,37,39,40,43]; 4 studies
did not state their assessment strategies [38,42,44,45]; one study
categorized them according to four levels of severity
(life-threatening, serious, clinically significant, or trivial) [41];
and one used NCC MERP categories together with the Common
Terminology Criteria for Adverse Events version 4.03, ranging
from mild (grade 1) to death (grade 5) [36]. Information
concerning the data source, the triggers, and the reviewer(s) are
detailed in Table 2.
Concerning the methodology, 5 studies came from the
“Automated Adverse Event Detection Collaborative,” which is
a consortium to facilitate the use of automated triggers in
pediatric hospitals [25,36,37,39,40,43]. They all used the same
approach, where an EHR-driven surveillance system was used,
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yet not providing detailed information on the software. Every
night, trigger reports were automatically generated for laboratory
results [37,40,43], medications levels in the blood [36,39], or
both [25]. A clinical analyst examined every trigger by
reviewing the EHR and interviewing care providers. The
potential AEs were reviewed by specialists: pharmacists,
physicians, endocrinologists, or anesthesiologists. The clinical
analyst met with a multidisciplinary team, the “Automated
Adverse Event Detection Steering Committee,” monthly to
present the results. Two studies used natural language processing
(NLP) to extract information from EHRs [41,44]. NLP is defined
as a technique extracting information from narrative text and
transforming it into structured text [41,46]. NLP is able to deal
with synonyms, negations, and abbreviations used in narrative
text. To build queries, SAS Text Miner tool [44] was used;
however, no further details were provided. Structured Query
Language [41] was used to identify AEs in the EHRs. The other
studies used (1) Electronic trigger-detection messages that were
sent automatically to two pharmacist reviewers [42], (2)
Computerized trigger alert system that sent an alert to the project
manager within 24 hours when conditions defined by the trigger
algorithm were detected [38], and (3) electronic algorithms
where triggers were identified automatically [45]. No further
details concerning the development, the algorithms, or the tools
used were given. Description of the methods are explained in
Table 3.
Table 1. Design and characteristics of the sample and population of the included studies.
SettingSample sizeTime frame
(months)
PopulationStudy
Diagnostic test accuracy studies
Not stated50026Not statedGerdes and Hardahl, 2013 [44]
General internal medicine25012Adults, exclusion of patients admitted
under observation status and cared for
by either of the two medical record
abstractors
O’Leary et al, 2013 [41]
Prevalence studies
Oncology
Hematology
39048ChildrenCall et al, 2014 [36]
General internal medicine
Surgical care
Emergency department
Intensive care unit (ICU)
Psychiatric unit
13,52612Children, exclusion weekend days for
5 months because of resource limita-
tions
Dickermann et al, 2011 [37]
Not statedNot stated3x1 monthAdultsLim et al, 2016 [42]
General internal medicine
Surgical care
Obstetrics or gynecology
4565AdultsMoore et al, 2009 [38]
Not statedNot stated21 for one trigger
and 16 for another
one
ChildrenMuething et al, 2010 [39]
Not stated54,24412Not statedNwulu et al, 2013 [45]
Pediatric ICU
Neonatal ICU
Cardiac ICU
Medical and surgical acute
care areas
Not stated52 for one trigger;
40 and 60 for the
others
ChildrenPatregnani et al, 2015 [43]
Pediatric ICU
Cardiac ICU
6,87236ChildrenShea et al, 2013 [40]
General internal medicine
Surgical care
Psychiatric unit
Neonatal
Cardiac ICU
Pediatric ICU
Not stated36 for hospital 1 and
51 for hospital 2
Children, exclusion of emergency
departments and ambulatory clinics
Stockwell et al, 2013 [25]
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Table 2. Data sources, triggers, and reviewers of included studies.
Reviewer(s)TriggersData sourceStudy
Diagnostic test accuracy studies
Not stated“Models,” not defined, identifying the
most common triggers and/or AEsb
Unstructured and semistructured narra-
tive texts in EHRsa
Gerdes and Hardahl, 2013 [44]
Experienced hospitalists and
physician-researcher (prior ex-
perience with the research
method)
Locally developed based on screening
criteria from the Harvard Medical
Practice Study and the IHId GTTe
Enterprise Data Warehouse: EHRs or
CPOESc; hospital and physician billing
systems; incident reporting system; and
admission or discharge or transfer with
nightly updates from activities occur-
ring in the preceding 24 h
O’Leary et al, 2013 [41]
Prevalence studies
Pharmacist and physicianWide use in similar population and
high likelihood to detect adverse drug
events
EHR: laboratory, pharmacy, electronic
medication administration record,
CPOE, and documentation functions
Call et al, 2014 [36]
CAf trainedIncreasing use in hospitals’ protocolsEHRsDickermann et al, 2011 [37]
Pharmacists, medication safety
pharmacist, and physician
Review of literature and detectable in
EHRs with reasonable PPVg
EHR supports all inpatient and ambula-
tory care clinical and documentation
activities
Lim et al, 2016 [42]
Study investigatorsMost common inpatient adverse drug
events
CPOE with decision support, EHR,
clinical event monitors
Moore et al, 2009 [38]
Endocrinologist, anesthesiolo-
gist, and frontline staff
AEs steering committeeClinical information system: computer-
ized clinical order entry, clinical docu-
mentation, electronic medication admin-
istration record, data storage repository,
and advanced clinical decision support
Muething et al, 2010 [39]
Not statedTest the usefulness of two medication
module triggers from the GTT pro-
posed by IHI
Locally developed electronic health and
prescription computer system (labora-
tory results and prescribing, except
some chemotherapy regimens) has
built-in checks to identify potential
prescribing errors (flagged through
warnings and alerts)
Nwulu et al, 2013 [45]
CA trained in the AE trigger
process
Clinical evidencesEHRsPatregnani et al, 2015 [43]
CA trained in the AE trigger
process
Clinical evidences and risks of deathsEHRs and Laboratory Information
System
Shea et al, 2013 [40]
CAMultidisciplinary review process us-
ing several review criteria
EHRsStockwell et al, 2013 [25]
aEHRs: electronic health records.
bAE: adverse event.
cCPOES: computerized provider order entry system.
dIHI: Institute for Healthcare Improvement.
eGTT: Global Trigger Tool.
fCA: clinical analyst.
gPPV: positive predictive value.
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Table 3. Overview of the automated trigger tool methodology.
Description of the methodStudy
Diagnostic test accuracy studies
(1) Extraction and preparation of all texts from the EHRsa; (2) Use of SAS Text Miner and the SAS Enterprise
Content Categorization software to build query models (natural language processing algorithms)
Gerdes and Hardahl, 2013 [44]
(1) Leveraging of various information systems in the EDWb; (2) Write Structured Query Language queries to
mimic work of a reviewer to identify potential AEsc based on trigger tool; (3) Two reviewers review the positive
EDW screens; (4) Another reviewer reviews narrative summaries and determines presence of AEs
O’Leary et al, 201 3[41]
Prevalence studies
(1) Software program conducts an extensive search of patient records for any type of order containing specific
medications and laboratory values; (2) Information generated into a report with patient-specific information;
(3) Review by two reviewers
Call et al, 2014 [36]
(1) Trigger reports automatically generated on a daily basis from the EHR by querying the Sunquest Laboratory
Information System for laboratory results; (2) Reviewer examined every trigger by reading the EHRs and inter-
viewing care providers
Dickermann et al, 2011 [37]
(1) Administration of a trigger drug to a patient automatically sent an electronic trigger-detection message to
two reviewers; (2) Trigger-detection messages were evaluated immediately after or during the day by both re-
viewers (consensus if disagreement); (3) Event reviewed by a medication safety pharmacist and then by a
physician for validation.
Lim et al, 2016 [42]
(1) The laboratory results and administered medications of each adult hospital patient were continuously monitored
by the computerized trigger alert system; (2) If any of the conditions defined was satisfied (trigger algorithm),
an alert was triggered, and data were collected by study investigators on the patient for a period of 72 hours after
the initial trigger firing to determine whether an adverse drug event had occurred.
Moore et al, 2009 [38]
(1) Combination of trigger tool approach with the clinical information system; (2) Every evening, automatic
detection of triggers are sent to the project manager (detection of event within 24 h); (3) Summary of the incident
automatically generated and sent to the appropriate staff on the unit involved
Muething et al, 2010 [39]
(1) The triggers identified electronically were linked to the electronic prescription records; (2) Two or more
positive triggers generated for the same patient, within a 24- or 72-hour interval (trigger-dependent) were
treated as one trigger; (3) The paper-based case notes were reviewed to identify any documentation of interest
Nwulu et al, 2013 [45]
(1) Generation of a trigger report by querying the Laboratory Information System (2) Reviewer investigated the
event by reading the patient’s EHRs and interviewing the clinical care team
Patregnani et al, 2015 [43]
(1) Generation of a trigger report by querying the Laboratory Information System (2) Reviewer investigated the
event by reading the patient’s EHRs and interviewing the clinical care team
Shea et al, 2013 [40]
(1) Automated trigger reports are generated from hospital information systems on a nightly basis; (2) Each
trigger report is examined by a reviewer and interviews conducted with care providers.
Stockwell et al, 2013 [25]
aEHRs: electronic health records.
bEDW: Enterprise Data Warehouse.
cAEs: adverse events.
Two studies compared results from automated trigger tool
methodology with those obtained via the manual trigger tool
method [41,44]. Six studies compared results with voluntary
incident reports but did not cross-verify their results with those
obtained via manually operated trigger-based tools; therefore,
we considered these prevalence studies [25,36,37,39,43,45].
The remaining 3 studies did not compare their results with those
obtained via any other method [38,40,42].
Quality Assessment
Figure 2 shows detailed results of the two quality assessments.
Diagnostic Test Accuracy Studies
In one of the 2 studies, the assessment of all domains was
hampered by poor reporting, and we were unable to judge the
risk of bias and concerns regarding applicability [44]. In the
other, we judged the concern regarding applicability of “patient
selection” as low [41]. We judged a high risk of bias in the “flow
and timing” domain and low bias risk and applicability concerns
for the “index test” and “reference standard” domains [41].
Prevalence Studies
A total of 9 studies were selected as prevalence studies via our
self-developed quality assessment tool (Multimedia Appendix
3). For “patient selection,” the bias risk was deemed low in
seven studies [25,36-38,40,42,43] and applicability concerns
were also low in eight of them [25,36-40,42,43]. We had no
concerns regarding applicability of the automatic detection
methods. As Figure 2 shows, for the other domain, we judged
low bias risk and concerns regarding applicability in a minority
of studies. In 5 studies, we judged a high risk of bias in the
“outcomes” domain, mainly because their AE definitions did
not reference those of the IHI or Food and Drug Administration,
and they lacked clearly stated prevalence outcomes
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[37,38,42,43,45]. We judged high bias risks in 3 studies
regarding the “automated detection method” domain [25,37,45].
In another, we judged the bias risk as high in the “reviewer or
algorithm selection” domain [45] because the triggers were not
consistently used or developed, and the reviewer lacked the
required profile (eg, experience and training).
Estimates of Diagnostic Test Accuracy, Prevalence,
and Reliability
Estimates of DTA can be found in Table 4, with additional
information concerning prevalence, preventability, and false
negative rates for AE categories. No information concerning
2x2 tables were available for all the triggers; thus, the decision
was made to use the AE categories.
Figure 2. Risk of bias and concerns regarding applicability assessments for diagnostic test accuracy studies (upper panel) and prevalence studies (lower
panel). Judgments are expressed as “low,” “high,” or “unclear” risk or concern for each of the domains (ie, “patient selection,” “index test”). The
percentages refer to the percentage of studies meeting the judgment low, high, or unclear risk of bias or concerns regarding applicability in each of the
domains. Quality Assessment tool for Diagnostic Accuracy Studies-2 (QUADAS-2) was used for the two diagnostic test accuracy studies and an in-house
developed tool was used to assess the 9 prevalence studies.
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Table 4. The table displays the estimates of diagnostic test accuracy in 2 studies comparing automated trigger-based tools with a manual trigger-based
tool as reference standard.
False negative
ratec (%)
Positive predictive
valueb, % (95% CI)
Prevalencea, %
(95% CI)
2x2 table for adverse
events (True positive
/ false positive /
false negative / true
negative)
Type of adverse eventsStudy
3056 (42.2-69.8)5.6 (3.6-7.6)28 / 22 / 12 / 436Pressure ulcerGerdes and Hardahl, 2013 [44]
45.552.2 (37.7-66.6)9.6 (5.9-13.3)24 / 22 / 20 / N/AdAdverse drug eventO’Leary et al, 2013 [41]
36.438.9 (16.4-61.4)2.8 (0.8-4.9)7 / 11 / 4 / N/AHospital acquired infection
44.455.6 (23.1-88)2 (0.3-3.7)5 / 4 / 4 / N/AOperative or procedural injury
62.560 (17.1-102.9)1.2 (−0.2 to 2.6)3 / 2 / 5 / N/AManifestation of poor glycemic
control
1000 (0-0)0 (0-0)0 / 8 / 2 / N/APressure ulcer
083.3 (53.5-113.2)2 (0.3-3.7)5 / 1 / 0 / N/AVenous thromboembolism
066.7 (13.3-120)0.8 (−0.3 to 1.9)2 / 1 / 0 / N/AAcute renal failure
00 (0-0)0 (0-0)0 / 0 / 0 / N/ADelirium
00 (0-0)0 (0-0)0 / 0 / 0 / N/AFall
1000 (0-0)0 (0-0)0 / 2 / 5 / N/AOther
aPrevalence is calculated by true positive/total number of patients.
bCalculated as triggers corresponding to an adverse event out of all triggers=true positive/(true positive+false positive).
cCalculated as false negative/(false negative+true positive).
dN/A: not applicable.
Across all the 11 studies, AE prevalence ranged from 0% to
17.9%, with a median of 0.8%. The PPV of all triggers to detect
AEs ranged from 0% to 100% across studies, with a median of
40%. Some triggers are used in different studies and have
different PPV values: (1) in 6 studies, hypoglycemia [25,37-41]
had a PPV ranging from 15.8% to 60%; (2) in 5 studies,
naloxone [25,36,41,42,45] had a PPV ranging from 20% to
91%; (3) in 4 studies, flumazenil [25,36,41,42] had a PPV
ranging from 38.9% to 83.3%; and (4) in 4 studies, protamine
[25,36,42,43] had a PPV ranging from 0% to 60%. We were
unable to determine the AE prevalence, PPV, preventability,
and severity in 40.4%, 10.5%, 71.1%, and 68.4% of the studies,
respectively. These studies did not report the overall number of
records analyzed, triggers, or AEs; or the studies did not
conducted the analysis concerned. Detailed results for each
trigger with prevalence, preventability, severity, and PPV are
presented in Figures 3 and 4. Only 1 study supplied information
on interrater reliability, reporting a kappa value of .52 to .78
[41].
Challenges and Author Proposed Solutions
The challenges reported by authors concerned the relative large
number of false alarms, the dependence of PPV on AE
prevalence, and incomplete patient records leading to missed
events. To reduce the fraction of false alarms, several authors
suggested to use a threshold value for the triggers used based
on patient characteristics [36,38,40,43]. For example, specific
disease states of patients must have triggers with different
threshold as the consequences might be stronger because of
their disease. Authors from one study suggested to measure
sensitivity and specificity instead of PPV, as latter is known to
be largely affected by AE prevalence [38]. Another author group
suggested to either improve completeness of patient information
documentation or to combine different data sources to increase
the chance to detect AEs as each data source contains different
information type [42].
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Figure 3. Prevalence, preventability, severity, and positive predictive value (PPV) for all the 11 studies. The figure begins with the results of all the
triggers or adverse events (AEs) combined, then for each group of trigger order from the most studied to the least studied (part 1). Severity levels based
on the National Coordinating Council for Medication Error Reporting and Prevention: D=an error that reached the patient and required monitoring or
intervention to confirm that it resulted in no harm to the patient; E=temporary harm to the patient and required intervention; F=temporary harm to the
patient and required initial or prolonged hospitalization; G=permanent patient harm; H=intervention required to sustain life; and I=patient death. H1:
hospital 1; H2: hospital 2.
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Figure 4. Prevalence, preventability, severity, and positive predictive value (PPV) for all the 11 studies. The figure begins with the results of all the
triggers or adverse events (AEs) combined, then for each group of trigger order from the most studied to the least studied (part 2). Severity levels based
on the National Coordinating Council for Medication Error Reporting and Prevention: D=an error that reached the patient and required monitoring or
intervention to confirm that it resulted in no harm to the patient; E=temporary harm to the patient and required intervention; F=temporary harm to the
patient and required initial or prolonged hospitalization; G=permanent patient harm; H=intervention required to sustain life; I=patient death. H1: hospital
1; H2: hospital 2; VT: venous thromboembolism; IR: incident report.
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Discussion
Aim of This Review and Principal Findings
The goal of this systematic review was to synthesize the
evidence concerning the development of a semi or fully
automated method of AE detection in EHRs using trigger tools.
The results show a broad variation in applied methods, selection
of triggers, and estimates of AE prevalence and trigger-based
PPVs. Insufficient reporting precluded full appreciation of the
risk of bias and concerns regarding applicability.
Our findings are in line with another systematic review focusing
on manual GTT [10]. Several interstudy differences can be
hypothesized to explain the heterogeneity in the observed study
estimates of AE prevalence and PPVs. These include the time
frame (range: 1-51 months); the sample size (range: 250-54,244
records); the data sources and EHR system types; the automated
approach; the review process; but also the differences in defining
AEs, its severity, and preventability.
In addition, the choice and definition of triggers (eg, INR ≥6
[41,45] and INR >4 [25,43]) affect overall and per-trigger PPV.
In some studies, only triggers identifying unique AEs are used
for analysis, leading to varying results for similar triggers.
Furthermore, the PPV is deemed to be strongly affected by the
study’s AE prevalence. We could not test for this because of
the reviewed studies’ heterogeneous definitions of prevalence.
These included AEs per 100 patients admitted, AEs per 1000
patient days, or AEs per month. The missing information
concerning the total number of patients included (36.4% of the
11 studies) hindered computation of prevalence estimates for
these studies. The PPV of the triggers ranged from 0% to 100%.
Even for the same trigger, high variability was observed.
Similar parallels can be observed regarding AEs’ severity. Even
when naloxone was used as a trigger in two hospitals in the
same study [25], although one hospital had a severity level of
96.4%, falling into category “temporary harm to the patient and
required intervention,” the other had a severity level 100%,
falling into the categories “permanent patient harm or patient
death.” Several included studies suggested improvement of PPV
values by limiting triggers to specific patient subpopulations,
or by modifying thresholds based on age or other patient
characteristics [36,40]. Moore et al [38] suggested using
sensitivity and specificity instead of PPV, as the former is less
affected by changes in AE incidence. The studies did not address
difficulties or opportunities regarding the implementation of
trigger tool–based methods, but we do not exclude that such
information can be found in more qualitative types of research
that we did not collect for this review.
The decision of several of the reviewed studies’ authors to
employ semiautomatic approaches or to focus mainly on ADEs
reflects the difficulty of detecting AEs fully automatically. The
extracted high proportion of false alarms in various studies is
likely explained in part by these difficulties. Although several
studies showed that automatic tools can detect up to 69% of
ADEs found manually, automatic detection of AEs overall
remains problematic [47-50]. In our review, the sensitivity to
detect AEs ranged from 0% to 100%. General AE detection
requires more advanced technology, such as NLP, which can
read and process free-text narrative [51,52], addressing complex
issues such as negation and lexical variation of terminology.
Previous research has suggested that automated AE detection
methods were superior to manual tools [26,53,54]. Automated
AE detection methods have the potential to screen large numbers
of patients to save valuable time, which would not be possible
by doing manually by human reviewers with the same accuracy.
Yet, timely intervention is an important factor to avoid
complications and patient harm when an AE is detected. Even
if PPVs are not high for all AEs, automated AE detection
methods provide an excellent alternative to the manual approach
by saving time and resources [14]. As shown by the systematic
review of Wang et al, the use of NLP with EHRs is still at its
infancy, and closer collaboration of NLP experts and clinicians
is missing [46]. Nevertheless, automated AE detection methods
are a promising approach for patient safety improvement.
Looking deeper into the individual studies via our quality
assessment tools, we realized that, for most, their methodology,
their results, or both were reported in ways that were unclear,
inconsistent, or incomplete, which challenged our risk of bias
and applicability assessments. Several studies failed to report
the number of records screened or the type of patients sampled.
These elements, however, are crucial for interpretation of the
various estimates and also for its reproducibility. In other
studies, the number of triggers or AEs remained unclear. AE
severity and preventability were not always reported, and the
variation in use of definitions for AEs, severity, and
preventability further hampered interpretation of estimates across
studies. Interestingly, the majority of studies lacked to report
PPV CIs, which is essential for the swift interpretation of the
estimate’s precision.
Although not part of our quality assessment tools, we detected
risk of selective outcome reprint in some studies. In these,
severity and/or preventability assessments are reported in the
Methods sections but not addressed in the Results section. Only
one study checked for the presence of triggers at admission [42].
Such triggers or AEs should typically be excluded from the
evaluation, as it cannot be targeted with interventions aiming
at improving quality of care. Furthermore, although a reviewer’s
expertise plays an important role in the detection of AEs,
information concerning their professional background,
experience, or training was mostly absent. Overall, there is
substantial room for improvement of the quality of reporting.
Limitations
Our decision to limit the inclusion criteria to studies concerning
semi or fully automated trigger tool–like methodologies
disqualified many studies, including those employing
recommendations from the Harvard Medical Practice Study
[28,55,56], machine learning [57], early warning systems
[58-61], or other methods [62,63]. However, it allowed us to
show that even within a narrow set of trigger-based tools,
methods and outcomes varied considerably. The decision to
exclude studies involving outpatients [62,64,65] or mixes of
inpatients and outpatients [66] further decreased the number of
eligible studies but increased the comparability of the patient
population evaluated. Nevertheless, the overall low number of
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eligible studies precluded statistical evaluation of the impact of
sources of variation and bias. The evaluation of diagnostic test
accuracy is generally hampered by the absence of a widely
accepted reference standard.
Conclusions
This systematic review provides an overview about the
application and outcomes of (semi) automatic trigger-based AE
detection tools. We observed but could not formally explain the
high degree of interstudy variation in reported estimates of
prevalence and PPV, even in cases where similar triggers were
tested. Although the AHRQ recently released common formats
for event reporting [67], which supports the implementation of
AE detection in the EHR, standards for the reporting of AE
detection studies using trigger tools are lacking, yet urgently
needed to overcome the methodological heterogeneity in future
studies. We need better standards for reporting in this field of
research to increase reproducibility, interpretation, and
avoidance of research waste. A more standardized use of
definitions of the types, severity, and preventability of AEs is
desirable. We therefore call for a set of recommendations for
the conduct and reporting of future studies and in the meantime,
suggest authors, peer reviewers, and editors to pay special
attention to complete reporting of study population, AE and
trigger definitions, experience, training, and background of
reviewers; methods employed to check for triggers and/or AEs
at patient admission; and complete reporting of outcome data
(numbers of triggers, nominators and denominators of the
prevalence, and PPV).
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Multimedia Appendix: Hausner et al.’s approach 
This is a Multimedia Appendix to a full manuscript published in the J Med Internet Res. For full 
copyright and citation information see http://dx.doi.org/10.2196/jmir.9901. 
 
From our personal bibliographic archive and references of systematic reviews, we located 62 papers for 
the trigger tool methodology. We randomly divided those papers into two sets of 31: (1) Development 
set and; (2) Validation set. From the development set, we extracted the frequency of free text terms for 
title and abstract fields and subject headings (MeSH) with the PubMed PubReMiner tool (a free web 
service for searches in MEDLINE). This process identified potential candidate terms for inclusion in the 
search strategy. The search strategy’s success was indicated by the number of results it returned and the 
sensitivity of the development and validation sets. The sensitivity is calculated by the number of papers 
found with the search strategy divided by the total number of papers in the set. For example, with the 
search strategy “trigger[tiab] OR triggers[tiab]”, we found 31 papers out of 31 of the development set 
among the 99,429, meaning that it has a sensitivity of 100%. However, a high sensitivity is not enough: 
the number of results should be low to have a precise strategy. Sensitivities of the development and 
validation sets both should be around 90% with a low number of results. The table below shows the 
various steps with the final result (conducted on October 21st, 2015). 
 
Search Strategy Results Sensitivity 
development set 
Sensitivity 
validation set 
trigger[tiab] OR triggers[tiab] 99,429 100% (31/31) 100% (31/31) 
(tool[tiab] OR tools[tiab]) AND (trigger[tiab] OR 
triggers[tiab]) 
2,637 100% (31/31) 93.6% (29/31) 
adverse[tiab] AND identif*[tiab] 50,525 80.7% (25/31) 87.1% (27/31) 
adverse[tiab] AND (trigger[tiab] OR triggers[tiab] 
OR safety[tiab] OR medical errors[mh]) 
68,266 90.3% (28/31) 93.6% (29/31) 
adverse[tiab] AND (trigger[tiab] OR triggers[tiab] 
OR detect*[tiab] OR medical errors[mh]) 
28,943 90.3% (28/31) 93.6% (29/31) 
adverse[tiab] AND (trigger[tiab] OR triggers[tiab] 
OR record[tiab] OR records[tiab] OR medical 
errors[mh]) 
14,154 90.3% (28/31) 93.6% (29/31) 
adverse[tiab] AND (trigger[tiab] OR triggers[tiab] 
OR chart[tiab] OR charts[tiab] OR medical 
errors[mh]) 
8,802 90.3% (28/31) 93.6% (29/31) 
(adverse[tiab] OR medical errors[mh]) AND 
(detect*[tiab] OR trigger[tiab] OR triggers[tiab]) 
AND (chart[tiab] OR charts[tiab] OR record[tiab] 
OR records[tiab]) 
1,681 74.2% (23/31) 83.9% (26/31) 
(adverse[tiab] OR trigger[tiab] OR triggers[tiab]) 
AND (detect*[tiab] OR identif*[tiab]) AND 
6,157 87.1% (27/31) 93.6% (29/31) 
(medical errors[mh] OR chart[tiab] OR 
charts[tiab] OR record[tiab] OR records[tiab]) 
(trigger[tiab] OR triggers[tiab]) AND 
(adverse[tiab] OR record[tiab] OR records[tiab]) 
AND (chart[tiab] OR charts[tiab] OR medical 
errors[mh]) 
191 77.4% (24/31) 83.9% (26/31) 
(trigger[tiab] OR triggers[tiab]) AND (chart[tiab] 
OR charts[tiab] OR identif*[tiab] OR record[tiab] 
OR records[tiab]) AND (adverse[tiab] OR 
medical errors[mh]) 
561 90.3% (28/31) 93.6% (29/31) 
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 4 
Phase 1: State the review question: To determine the sensitivity and specificity of the Global Trigger 5 
Tool in detecting adverse events in adult inpatients with an electronic/automatic approach, using the 6 
manual GTT application as the reference standard. 7 
 8 
Patients (setting, intended use of index test, presentation, prior testing): 
All patients hospitalized for at least 48 hours (inpatient) with any specific disease 
Index test(s): 
Global Trigger Tool or a modified version (added/removed/modified triggers) used in a semi- or fully 
automatic way 
Comparator test:  
None 
Reference standard and target condition:  
Manual Global Trigger Tool or a modified version (added/removed/modified triggers) 
 9 
Flow diagram of the study 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
* Refers to signaling questions of the original QUADAS-2 tool 
† Refers to signaling questions added to the original QUADAS-2 tool 
DOMAIN 1: PATIENT SELECTION 
A. Risk of bias: Could the selection of patients have introduced bias?  
Describe methods of patient selection: 
 
 
 
1. Was a consecutive or random sample of patients enrolled? Yes / No / Unclear * 
If all accessible patients were selected as a sample or if the process of sampling was 
done with the method of random sampling, the question will be answered as “yes”. 
2. Was a case-control design avoided? Yes / No / Unclear * 
We excluded case-control studies, as these were deemed inappropriate; therefore, this 
question will not be used. 
3. Did the study avoid inappropriate exclusions? Yes / No / Unclear * 
This question will be answered with “no” if patients are excluded because of conditions 
known to be associated with false negative or false positive results. In these situations, 
automated trigger tool may fail (over/underdiagnose adverse events). Excluding such 
patient record forms may artificially inflate estimates of diagnostic test accuracy.  
 
RISK: LOW / HIGH / UNCLEAR 
B. Applicability: Are there concerns that the included patients and setting do not match the 
review question?  
Describe included patients (advanced vs early disease, symptoms, setting, prior testing, 
presence of alternative conditions, demographic features, intended use of the test, 
inpatient duration): 
 
 
If a study did not meet the patient population as described in the objective there will be a high 
concern regarding its applicability.  
 
 CONCERN: LOW / HIGH / UNCLEAR 
  
* Refers to signaling questions of the original QUADAS-2 tool 
† Refers to signaling questions added to the original QUADAS-2 tool 
DOMAIN 2: INDEX TEST 
A. Risk of Bias: Could the conducting or interpretation of the index test have introduced bias? 
Describe the index test and how it was conducted and interpreted: 
 
Description of the preventability  
 
1. Were the index test results interpreted without knowledge of the results of the 
reference standard? Yes / No / Unclear * 
Less important for objective tests or if index test is interpreted prior to reference standard.  
2. Were the adverse events defined based on the U.S Food & Drug Administration 
(FDA) definition and/or on the Institute for Healthcare Improvement (IHI) definition? 
Yes / No / Unclear † 
FDA definition: “Adverse event means any untoward medical occurrence associated with 
the medical intervention(s) at the hospital, whether or not considered drug related.” 
(https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32) 
3. Was the assessment of severity of the adverse events based on the National 
Coordinating Council for Medication Error Reporting and Prevention (NCC MERP)? 
Yes / No / Unclear † 
− FDA definition: “Adverse event means any untoward medical occurrence 
associated with the medical intervention(s) at the hospital, whether or not 
considered drug related.” 
 (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32) 
− IHI definition: “Any noxious or unintended event occurring in association with 
medical care.” (Griffin FA, Resar RK. IHI Global Trigger Tool for measuring 
adverse events. Institute for Healthcare Improvement Innovation Series White 
Paper. 2009.) 
  
4. Did the development of the algorithm involve clinician(s) and was it based on a test 
set or an empirical approach? Yes / No / Unclear † 
Involvement of a clinician is assumed/shown to improve validity as well as an empirical 
development approach (https://www.ncbi.nlm.nih.gov/pubmed/18487779; 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909812/).  
RISK: LOW / HIGH / UNCLEAR 
  
B. Applicability: Are there concerns that the index test, its conducting, or its interpretation differ 
from the review question? 
* Refers to signaling questions of the original QUADAS-2 tool 
† Refers to signaling questions added to the original QUADAS-2 tool 
If test conducting, technology, setting or interpretation differ from your review question, the results 
may not be applicable. Example: a higher ultrasound transducer frequency has been shown to 
improve sensitivity for the evaluation of patients with abdominal trauma.  
CONCERN: LOW / HIGH / UNCLEAR 
  
* Refers to signaling questions of the original QUADAS-2 tool 
† Refers to signaling questions added to the original QUADAS-2 tool 
DOMAIN 3: REFERENCE STANDARD 
A. Risk of Bias: Could the reference standard, its conduct, or its interpretation have introduced 
bias? 
Describe the reference standard and how it was conducted and interpreted: 
 
 
1. Is the reference standard likely to correctly classify the target condition? Yes / No / 
Unclear * 
We are aware that there is no globally accepted reference standard in this field but reason 
that the full manual chart review and the manual version of the GTT are at the moment 
the most sensitive methods to detect AEs, although we lack empirical data on the 
misclassification rates of the full manual chart review and the manual version of the GTT. 
In this situation, we judged yes if a full manual chart review or a manual version of the 
GTT were used, and no evidence was found in the study report that was suggestive of 
potential sources of bias related to the use/development of the full manual chart review 
and the manual version of the GTT. 
2. Were the reference standard results interpreted without knowledge of the results of 
the index test? Yes / No / Unclear * 
This question will be scored as “yes” if it is explicitly stated that the adverse event detection 
occurs without knowledge of the automatic GTT results. The reference standard should 
be interpreted blind to index test results. Related to degree of subjectivity and order of 
tests. 
3. Is the inter-rater reliability clearly stated and sufficiently high? Yes / No / Unclear † 
Although a clinical diagnostic test accuracy study should be conducted after reliability is 
more or less established, in the field of GTT, the evidence on reliability is variable. For this 
reason, we added a signalling question regarding reliability. We classified “yes” if the inter-
rater reliability was assessed with sound methods, and was judged to be acceptably high.  
RISK: LOW / HIGH / UNCLEAR 
 
B. Applicability: Are there concerns that the target condition as defined by the reference 
standard does not match the question? 
Reference standard outcomes are decisive: if the reference standard does not detect the target 
condition defined in the review question, results may not be applicable. It is critical to choose a 
valid/optimal reference standard. 
CONCERN: LOW / HIGH / UNCLEAR 
* Refers to signaling questions of the original QUADAS-2 tool 
† Refers to signaling questions added to the original QUADAS-2 tool 
 
DOMAIN 4: FLOW AND TIMING 
A. Risk of Bias: Could the patient flow have introduced bias? 
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
 
 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
 
1. Was there an appropriate interval between index test and reference standard? Yes 
/ No / Unclear * 
Delays between tests can cause misclassification due to recovery or progression to more 
advanced disease. The length of time which may cause such bias will vary between 
conditions. 
This item is not applicable to the comparison between automated versus full manual chart 
review or the manual version of the GTT, due to the retrospective nature of both tools. We 
typically scored yes, unless there was evidence that the time period verified by the manual 
and automated version of the tools differed. In cases where the latter was true, we judged 
“no.” 
2. Were all patients included in the analysis? Yes / No / Unclear * 
This question will be scored as "yes" if all patients who were recruited into the study were 
included in the analysis. No is scored if one or more patients are missing from the 2x2 
table. As the study prevalence of AEs can be as low as 2%, we judged high risk of bias if 
6% or more of the patients were missing from the 2x2 table–assuming that one-third of 
those missing would not be random, potentially affecting our estimates of the prevalence. 
3. Was the completeness of electronic health records (EHRs) data discussed and 
addressed? Yes / No / Unclear † 
If yes, the risk of bias will be lower, since it takes into account missing data for the analysis. 
 
RISK: LOW / HIGH / UNCLEAR 
 
Multimedia Appendix: Trigger tool Quality Assessment Tool 
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STATE your review question here, and answer all signalling questions and judgments in 
light of this review question.  
1. To determine the prevalence of AEs as detected by an electronic/automated or semi-
automatic trigger tool in various adult inpatient populations.   
2. To describe the reliability of electronic/automated trigger tools  
3. To explore methods of phenotyping if adverse event detection in EHRs was used in the 
international literature. 
P Patient records of patients hospitalized at least 48 hours (inpatient) with any specific disease 
admitted to any ward 
I Global Trigger Tool or a modified version (added/removed/modified triggers) used in an 
automatic or semi-automatic way 
C Not applicable 
O Prevalence overall, by type of AE, and by type of hospital or ward. 
  
DOMAIN 1A: PATIENT SELECTION 
Describe methods of patient selection: 
 
 
 
 
A. Risk of bias: Could the selection of patient records have introduced bias?  
1.  Was the participation rate of eligible persons at least 50%? Yes / No / Unclear 
If the rate is less, this likely introduces bias (From http://www.nhlbi.nih.gov/health-
pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort). 
2. Was a consecutive or random sample of patient records enrolled? Yes / No / Unclear 
Reflect if all the subjects selected or recruited were from the same or similar populations 
(including the same time period)? Were inclusion and exclusion criteria for being in the 
study pre-specified and applied uniformly to all participants in a consecutive manner? If 
all accessible patient records were selected as a sample or if the process of sampling was 
done with the method of random sampling, this question will be answered as “yes”.  
3. Did the study consider patients covering a broad range of indications for 
hospitalisation? Yes / No / Unclear 
This question will be answered with “no” when patients with very different profiles are not 
considered by exclusion from study entry. Such exclusions are highly likely to alter the 
estimates of prevalence. This is a situation where GTT might over/underestimate adverse 
events. For example: exclusion of certain groups of patients due to extended lengths of 
stay or high numbers of transfers. 
RISK: LOW / HIGH / UNCLEAR 
B. Applicability: Are there concerns that the included patients and setting do not match the 
review question?  
If a study did not meet the patient population as described in the objective there will be a high 
concern regarding its applicability. In this specific review, we allow for a broad range of settings 
and study populations.  
CONCERN: LOW / HIGH / UNCLEAR 
  
DOMAIN 1B: REVIEWER/ALGORITHM SELECTION 
 
 
A. Risk of bias: Could the selection of reviewers/algorithms have introduced bias?  
1. Was the selection of the reviewer(s) based on his/her experience and/or 
professional background in the clinical setting? Yes / No / Unclear 
A lack of experience on the part of the reviewer(s) in the clinical setting may introduce 
bias. For reviewers with appropriate clinical backgrounds the bias might be lower 
concerning misclassification rates. 
 
2. Were the reviewer(s) trained on using and applying trigger tool methodology?  Yes 
/ No / Unclear 
A lack of trigger tool training and application knowledge may introduce bias. For 
reviewer(s) with more training the bias might be lower. 
 
3. Do the reviewer(s) have experience in applying the trigger tool or another 
retrospective chart review methodology? Yes / No / Unclear 
A lack of trigger tool experience may introduce bias. For reviewer(s) with more trigger tool 
experience the bias might be lower. 
 
4. Did the study use a test and validation sets to develop the algorithm? Yes / No / 
Unclear 
The development of EHR algorithms always leads to choices (e.g., whether they should 
be geared towards sensitivity or precision). Using the split-half method is crucial to assess 
the efficacy of the proposed algorithm. 
 
5. Is the inter-rater reliability clearly stated and sufficiently high? Yes / No / Unclear 
Although a clinical diagnostic test accuracy study should be conducted after reliability is 
more or less established, in the field of GTT, the evidence on reliability is variable. For this 
reason, we added a signalling question regarding reliability. We classified “yes” if the inter-
rater reliability was clearly assessed with sound methods, and was judged to be 
acceptably high. 
RISK: LOW / HIGH / UNCLEAR 
Describe methods to sample patients to be included in the reliability estimations: 
State the determined number of reviewers:  
State the number of patient records included in the reliability estimations:  
State the number of replicated observations:  
Describe the reviewer characteristics (e.g., training, experience):  
Did raters judge/analyse the records independently (e.g., stage 1 screening)? 
B. Applicability: Are there concerns that the reviewer(s) do not match the review question?  
For example, if the profile(s) of the reviewer(s) applying the trigger tool in the study differ 
substantially from those of healthcare professionals who would apply it in clinical practice, a high 
concern may arise.  
CONCERN: LOW / HIGH / UNCLEAR  
DOMAIN 2: AUTOMATIC DETECTION METHOD 
Description of the method 
 
 
 
A. Risk of Bias: Could the conducting or interpretation of the index test have introduced bias? 
1. Was the application of the algorithms fully automatic? Yes / No / Unclear 
Algorithms implemented in a semi-automatic way with different process steps are 
expected to introduce more bias (semi-automatic processes being more prone to errors). 
2. Did the development of the algorithm involve clinician(s) and was it based on a test 
set or an empirical approach? Yes / No / Unclear 
Involvement of a clinician is assumed/shown to improve validity as well as an empirical 
development approach (https://www.ncbi.nlm.nih.gov/pubmed/18487779; 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909812/).  
3. Was the selection of triggers based on literature review and/or consultation with a 
group of experts in the field? Yes / No / Unclear 
Empirical evidence or at least a biological rationale should exist for each of the triggers 
included in the tool. This particularly applies to new triggers not part of the original IHI set 
of triggers.  
 
4. Are the triggers used the same for all settings and/or the hospitals participating in 
the study? Yes / No / Unclear 
If differing versions of triggers are in use across participating units, a strong rationale 
should have been given to adapt them. For example, it is acceptable to adapt triggers 
according to national circumstances where a specific drug is not licensed. 
5. Was the presence of any adverse event checked/controlled at the admission of the 
patient to the unit/hospital? Yes / No / Unclear 
If not, the unit/hospital might conclude that those AEs were the consequences of their own 
care to the patients. 
RISK: LOW / HIGH / UNCLEAR 
 B. Applicability 
1. Are there concerns that the trigger tool test, its conducting, or its interpretation 
differ from the review question? 
If test conducting, technology, setting or interpretation differ from your review question, 
the results may not be applicable. For example: triggers are not related to the IHI GTT; 
AEs captured in the study are more triggers than AEs.  
  
CONCERN: LOW / HIGH / UNCLEAR  
DOMAIN 3: OUTCOMES 
A. Risk of Bias: Could the definition of outcomes have introduced bias? 
Describe the definition(s) of AE:  
 
Describe the how prevalence was measured: 
 
Describe your judgment, if you deem the definitions to be standard, or deviating from our review 
definitions and describe if you deem reliability sufficiently high:  
 
1. Were the adverse events defined based on the U.S Food & Drug Administration (FDA) 
definition and/or on the Institute for Healthcare Improvement (IHI) definition? Yes / No / 
Unclear 
− FDA definition: “Adverse event means any untoward medical occurrence associated with 
the medical intervention(s) at the hospital, whether or not considered drug related.” 
(https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32) 
− IHI definition: “Any noxious or unintended event occurring in association with medical care.” 
(Griffin FA, Resar RK. IHI Global Trigger Tool for measuring adverse events. Institute for 
Healthcare Improvement Innovation Series White Paper. 2009.) 
 
2. Was the assessment of the adverse events’ severity based on the National Coordinating 
Council for Medication Error Reporting and Prevention (NCC MERP)? Yes / No / Unclear 
Classification of the AEs’ severity follow: http://www.nccmerp.org/sites/default/files/indexColor2001-06-
12.pdf 
 
3. For prevalence, were the outcome measures (dependent variables) clearly defined? Yes 
/ No / Unclear 
A lack of a clear outcome measure definition might lead to different results, thus introducing 
bias.  
 
4. For prevalence, were the definitions consistently applied across all study participants? 
Yes / No / Unclear 
 If not, AE prevalence values might differ between patient groups, thus introducing bias.  
 
RISK: LOW / HIGH / UNCLEAR 
 
  
DOMAIN 4: FLOW AND TIMING 
A. Risk of Bias: Could the patient flow have introduced bias? 
1. Was the completeness of electronic health records (EHRs) data discussed and 
addressed? Yes / No / Unclear 
If yes, the risk of bias may be lower, since it takes into account missing data for the 
analysis. 
2. Were all patients included in the analysis of prevalence? Yes / No / Unclear 
This question will be scored as "yes" if all patients who were recruited into the study were 
included in the analysis. No is scored if one or more patients are missing. As the study 
prevalence of AEs can be as low as 2.x%, we judge high risk of bias if 10% or more of the 
patients are omitted from the AE prevalence calculations. This assumes that one third of 
the missing would not be at random, potentially affecting our prevalence estimates. 
 
RISK: LOW / HIGH / UNCLEAR 
 
 
